Diabetes mellitus increased the odds of clopidogrel resistance (OR 1.55; 95% CI 1.22–1.97), whereas male sex, current smoking, and the CYP2C19 2 GG genotype (OR 0.45; 95% CI 0.26–0.78) lowered odds.
Meta-Analysis (n=11,786)
What are the sociodemographic, clinical, and genetic predictors of clopidogrel resistance in patients with ischemic stroke or TIA?
65 studies (11,786 patients) of adults (≥18 years) with ischemic stroke or TIA
Clopidogrel resistance
Non-resistant patients
Sociodemographic, clinical, and genetic predictors of clopidogrel resistancesurrogate
Clopidogrel resistance in stroke/TIA patients is multifactorial, driven by older age, diabetes, poor glycemic control, female sex, non-smoking status, and genetic factors.
Effect estimate: OR 1.55 (95% CI 1.22-1.97)
Abstract Background and aims Clopidogrel resistance is prevalent in patients with ischemic stroke or transient ischemic attack (TIA), leading to recurrent cerebrovascular events. However, reported associations for its risk factors are inconsistent. This systematic review and meta-analysis quantifys the sociodemographic, clinical, and genetic predictors of clopidogrel resistance in patients with ischemic stroke or TIA. Methods Following PRISMA guidelines (PROSPERO: CRD420251113725), we systematically searched PubMed, Embase, Scopus, and Web of Science from inception to June 2025. Eligible studies included adults (≥18 years) with ischemic stroke or TIA reporting extractable data for clopidogrel-resistant and non-resistant groups. Results Sixty-five articles (11,786 patients) were included in this systematic review, of which 34 studies (6,053 patients) were included in the analysis. Compared with non-resistant patients, those with clopidogrel resistance were slightly older (MD 1.92 years; 95% CI 1.15–2.68) and had higher HbA1c (MD 0.27%; 95% CI 0.07–0.46), fasting blood glucose (MD 0.62 mmol/L; 95% CI 0.24–0.99), and total cholesterol (MD 0.09 mmol/L; 95% CI 0.004–0.18), but lower hemoglobin levels (MD −0.54 g/dL; 95% CI −1.04 to −0.04). While diabetes mellitus was associated with higher odds of resistance (OR 1.55; 95% CI 1.22–1.97), male sex (OR 0.75; 95% CI 0.65–0.86), current smoking (OR 0.74; 95% CI 0.56–0.97), and the CYP2C19 2 GG genotype (OR 0.45; 95% CI 0.26–0.78) were associated with lower odds of resistance. Conclusions Clopidogrel resistance in stroke/TIA patients is multifactorial, driven by a specific profile of demographic ( age, sex, smoking), metabolic (diabetes, glycemic control) and genetic (CYP2C19) factors. Conflict of interest Yusof M. Omar: Nothing to disclose, Abdullah Almarfadi: Nothing to disclose, Fawaz K Alfahmi: Nothing to disclose, Omar Hammam Salloum : Nothing to disclose, Jamal Ahmad: Nothing to disclose, Abdelrahman Abdelhameed Hashem: Nothing to disclose, Moamen Samy Syaj: Nothing to disclose, Omnia Samy El-Sayed : Nothing to disclose.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yusof Mohamed Omar
Mansoura University
Abdullah Almarfadi
University Ferhat Abbas of Setif
Fawaz K Alfahmi
Taif University
European Stroke Journal
Mansoura University
Assiut University
Zagazig University
Building similarity graph...
Analyzing shared references across papers
Loading...
Omar et al. (Fri,) conducted a meta-analysis in Ischemic stroke or TIA (n=11,786). Risk factors for clopidogrel resistance vs. Non-resistant patients was evaluated on clopidogrel resistance (OR 1.55, 95% CI 1.22-1.97). Diabetes mellitus increased the odds of clopidogrel resistance (OR 1.55; 95% CI 1.22–1.97), whereas male sex, current smoking, and the CYP2C19 2 GG genotype (OR 0.45; 95% CI 0.26–0.78) lowered odds.
synapsesocial.com/papers/69fd7e42bfa21ec5bbf06730 — DOI: https://doi.org/10.1093/esj/aakag023.938